Literature DB >> 23957859

HBcAg-specific IL-21-producing CD4+ T cells are associated with relative viral control in patients with chronic hepatitis B.

L Li1, M Liu, L-W Cheng, X-Y Gao, J-J Fu, G Kong, X Feng, X-C Pan.   

Abstract

Function exhaustion of specific cytotoxic CD8+ T cell in chronic virus infection partly results from the low levels of CD4 help, but the mechanisms by which CD4 help T cell required to control hepatitis B virus infection are not well understood. In this study, we investigated the role of interleukin-21-producing CD4+ T cell response in viral control of hepatitis B virus infection. HBcAg-specific interleukin-21-producing CD4+ T cells in blood were detected in patients with hepatitis B virus infection. Patients with acute hepatitis B had greater HBcAg-specific interleukin-21-producing CD4+ T cells in blood compared with chronic hepatitis B patients, and there was no statistical significance between immune active chronic hepatitis B patients and inactive healthy carrier patients for these cells, whereas frequencies of these cells negatively correlated with HBV DNA levels but positively correlated with HBc18-27-specific IFN-γ-producing CD8+ T cells. Moreover, interleukin-21 sustained HBc18-27-specific CD8+ T cells in vitro, and interleukin-21 production by HBcAg-specific IL-21-producing CD4+ T cells of acute hepatitis B patients enhanced IFN-γ and perforin expression by CD8+ T cells from chronic hepatitis B patients. Our results demonstrate that HBcAg-specific interleukin-21-producing CD4+ T cell responses might contribute to viral control by sustaining CD8+ T cell antiviral function.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23957859     DOI: 10.1111/sji.12099

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  14 in total

Review 1.  Role of interleukin-21 in HBV infection: friend or foe?

Authors:  Yongyin Li; Libo Tang; Jinlin Hou
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

2.  [A recombinant adenovirus vector carrying murine interleukin-21 gene controls chronic HBV infection in mice].

Authors:  Xue-Ping Gao; Yang Zhou; Xin-Chun Zheng; Xuan Yi; Li-Bo Tang; Jin-Lin Hou; Yong-Yin Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-11-20

Review 3.  Interleukin-21: a double-edged sword with therapeutic potential.

Authors:  Rosanne Spolski; Warren J Leonard
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

Review 4.  Immunopathogenesis of chronic hepatitis B.

Authors:  Irina P Balmasova; Nikolay D Yushchuk; Ospan A Mynbaev; Nageswara R Alla; Elena S Malova; Zhongjie Shi; Chang-Lu Gao
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 5.  IL-21 and T Cell Differentiation: Consider the Context.

Authors:  Yuan Tian; Allan J Zajac
Journal:  Trends Immunol       Date:  2016-07-04       Impact factor: 16.687

6.  A fusion DNA vaccine encoding middle version of HBV envelope protein fused to interleukin-21 did not enhance HBV-specific immune response in mice.

Authors:  Ye Zhang; Wen-Jing Su; Jue Wang; Xue-Fan Bai; Chang-Xing Huang; Jian-Qi Lian
Journal:  Viral Immunol       Date:  2014-09-11       Impact factor: 2.257

7.  Interleukin-21 responses in patients with chronic hepatitis B.

Authors:  Jie Li; Wanhua Ren; Wei Ma; Jiao Zhang; Jun Shi; Chengyong Qin
Journal:  J Interferon Cytokine Res       Date:  2014-09-22       Impact factor: 2.607

Review 8.  Interleukin-21 and T follicular helper cells in HIV infection: research focus and future perspectives.

Authors:  Suresh Pallikkuth; Savita Pahwa
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 9.  T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance.

Authors:  B Ye; X Liu; X Li; H Kong; L Tian; Y Chen
Journal:  Cell Death Dis       Date:  2015-03-19       Impact factor: 8.469

10.  Disruption of IL-21 signaling affects T cell-B cell interactions and abrogates protective humoral immunity to malaria.

Authors:  Damián Pérez-Mazliah; Dorothy Hui Lin Ng; Ana Paula Freitas do Rosário; Sarah McLaughlin; Béatris Mastelic-Gavillet; Jan Sodenkamp; Garikai Kushinga; Jean Langhorne
Journal:  PLoS Pathog       Date:  2015-03-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.